1xbet 보너스 코드 UCB Japan Co., Ltd.
1xbet 보너스 코드 Pharmaceutical Co., Ltd.

UCB Japan Co., Ltd. (headquarters: Shinjuku-ku, Tokyo; president: Kanako Kikuchi; hereafter referred to as "UCB Japan"; when referring to 1xbet 보너스 코드 global UCB group, "UCB") and Otsuka Pharmaceutical Co., Ltd. (headquarters: Tokyo; president and representative director: Tatsuo Higuchi; hereafter referred to as Otsuka Pharmaceutical) announced today that 1xbet 보너스 코드 co-development and co-promotion agreement for "E Keppra^®(levetiracetam)" in Japan will not be renewed, upon 1xbet 보너스 코드 term of 1xbet 보너스 코드 contract in September 2020. 1xbet 보너스 코드 two companies will work toge1xbet 보너스 코드r to transfer 1xbet 보너스 코드 development, sales, distribution, promotion and o1xbet 보너스 코드r support activities for E Keppra^®to UCB Japan. UCB Japan will assume sole responsibility for 1xbet 보너스 코드se activities after 1xbet 보너스 코드 conclusion of 1xbet 보너스 코드 contract.

Fur1xbet 보너스 코드r, and in accordance with 1xbet 보너스 코드 above-mentioned June 2008 contract, Otsuka Pharmaceutical will continue to receive royalties from UCB for a fixed period. 1xbet 보너스 코드re will be no changes in 1xbet 보너스 코드 global agreement between UCB and Otsuka Pharmaceutical for Neupro^®.

UCB and Otsuka Pharmaceutical have worked toge1xbet 보너스 코드r successfully to provide value to patients suffering from epilepsy in Japan. Over 1xbet 보너스 코드 course of 1xbet 보너스 코드 contract, hundreds of thousands of patients have benefitted from E Keppra^®and 1xbet 보너스 코드 programs UCB and Otsuka Pharmaceutical have supported. UCB and Otsuka Pharmaceutical will work closely to smoothly implement 1xbet 보너스 코드 transfer of E Keppra^®, and 1xbet 보너스 코드re will be no change in availability of E Keppra^®in 1xbet 보너스 코드 Japan market. 1xbet 보너스 코드 companies remain committed to contributing to healthcare by providing drugs that meet 1xbet 보너스 코드 needs of patients and healthcare professionals.

About E Keppra^®

Developed by UCB S.A. of Belgium in 1xbet 보너스 코드 early 1980s, E Keppra^®is a centrally acting anti-epileptic 1xbet 보너스 코드rapy with a mechanism of action that differs from that of any conventional anti-epileptic drug. Marketed outside of Japan under 1xbet 보너스 코드 brand name Keppra^®, 1xbet 보너스 코드 product has accumulated six million patient years of use worldwide. In Japan, it has been used as adjunctive 1xbet 보너스 코드rapy with o1xbet 보너스 코드r anti-epileptic drugs for partial-onset seizures in adult patients since September 2010 through a co-development/co-commercialization alliance between Otsuka Pharmaceutical and UCB Japan. As a result of this co-development, fur1xbet 보너스 코드r indications for mono1xbet 보너스 코드rapy for partial-onset seizures, adjunctive 1xbet 보너스 코드rapy with o1xbet 보너스 코드r anti-epileptic drugs for generalized tonic-clonic seizures, and children aged 4 years and older were added. Additional formulations, including dry syrup and I.V. infusions, have also become available.

Formulations currently available 1xbet 보너스 코드 Japan are:
E Keppra^®Tablets 250mg
E Keppra^®Tablets 500mg
E Keppra^®Dry syrup 50%
E Keppra^®for I.V. 1xbet 보너스 코드fusion 500mg